Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into a licensing agreement with A. Menarini Korea Limited (“Menarini Korea”), a wholly owned subsidiary of Menarini Group, for […]

Read more

Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

/in

genex Bone Graft Substitute upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. marketZimmer Biomet will exclusively distribute genex Bone Graft Substitute in the U.S. Keele, UK, 22 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing […]

Read more

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

/in

Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more

Read more

Leucid Bio Chief Scientific Officer John Maher publishes new research on pCAR technology

/in

New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets and target combinations in pre-clinical liquid and solid tumour cell lines/models John Maher has been an early pioneer of CAR T-cell immunotherapy with a focus on solid tumours London, UK […]

Read more

Neuraxpharm appoints Tom Coogan as new Country Manager for Ireland

/in

Europe’s leading central nervous system specialty company strengthens its management team in Ireland and reinforces its growth strategy Dusseldorf and Barcelona, March 15, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that Tom Coogan has been appointed Country Manager for Ireland. The appointment reinforces […]

Read more
© Optimum Strategic Communications.